Stockscreener 앱 받기
17.65
0.11%
-0.02
시간 외 거래:
17.65
전일 마감가:
$17.67
열려 있는:
$17.62
하루 거래량:
679.86K
Relative Volume:
1.73
시가총액:
$6.25B
수익:
$4.89B
순이익/손실:
$-263.00M
주가수익비율:
-22.82
EPS:
-0.7734
순현금흐름:
$-167.84M
1주 성능:
+5.50%
1개월 성능:
+2.86%
6개월 성능:
+20.81%
1년 성능:
+8.28%
1일 변동 폭
$17.38
$18.09
1주일 범위
$16.25
$18.09
52주 변동 폭
$10.45
$18.09
Bausch Lomb Corp Stock (BLCO) Company Profile
명칭
Bausch Lomb Corp
전화
908-541-5456
주소
520 APPLEWOOD CRESCENT, VAUGHAN
Compare BLCO vs ISRG, BDX, ALC, MDLN, RMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BLCO
Bausch Lomb Corp
|
17.65 | 6.26B | 4.89B | -263.00M | -167.84M | -0.7734 |
|
ISRG
Intuitive Surgical Inc
|
499.53 | 177.84B | 10.06B | 2.88B | 2.49B | 7.876 |
|
BDX
Becton Dickinson Co
|
182.47 | 51.97B | 21.92B | 1.76B | 2.63B | 6.1223 |
|
ALC
Alcon Inc
|
83.22 | 40.42B | 10.19B | 1.05B | 1.38B | 2.1044 |
|
MDLN
Medline Inc
|
47.60 | 39.70B | 27.43B | 1.27B | 1.01B | 1.5829 |
|
RMD
Resmed Inc
|
256.29 | 37.72B | 5.40B | 1.49B | 1.78B | 10.12 |
Bausch Lomb Corp Stock (BLCO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-05 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2025-12-11 | 업그레이드 | Citigroup | Neutral → Buy |
| 2025-12-02 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2025-10-01 | 개시 | Goldman | Neutral |
| 2025-05-02 | 재확인 | H.C. Wainwright | Buy |
| 2025-03-28 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2024-12-11 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2024-12-02 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2024-10-15 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2024-07-10 | 개시 | Raymond James | Outperform |
| 2024-05-06 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2024-01-04 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2023-12-12 | 개시 | Stifel | Hold |
| 2023-10-03 | 재개 | Evercore ISI | Outperform |
| 2023-05-30 | 재개 | Morgan Stanley | Equal-Weight |
| 2023-03-09 | 개시 | Needham | Hold |
| 2022-12-21 | 개시 | Barclays | Equal Weight |
| 2022-09-12 | 개시 | H.C. Wainwright | Buy |
| 2022-07-26 | 개시 | RBC Capital Mkts | Outperform |
| 2022-06-24 | 개시 | Evercore ISI | Outperform |
| 2022-06-06 | 개시 | Citigroup | Buy |
| 2022-05-31 | 개시 | Deutsche Bank | Hold |
| 2022-05-31 | 개시 | Goldman | Neutral |
| 2022-05-31 | 개시 | Guggenheim | Buy |
| 2022-05-31 | 개시 | JP Morgan | Neutral |
| 2022-05-31 | 개시 | Jefferies | Buy |
| 2022-05-31 | 개시 | Morgan Stanley | Equal-Weight |
| 2022-05-31 | 개시 | Wells Fargo | Overweight |
| 2022-05-11 | 개시 | Cowen | Outperform |
모두보기
Bausch Lomb Corp 주식(BLCO)의 최신 뉴스
Bausch + Lomb price target raised to $15 from $13 at BofA - TipRanks
Breaking Down Bausch & Lomb: 6 Analysts Share Their Views - Benzinga
Bausch + Lomb price target raised to $21 from $20 at Citi - TipRanks
Stifel raises Bausch & Lomb stock price target on strong Miebo sales - Investing.com
Bausch + Lomb Corporation (NYSE:BLCO) Q4 2025 Earnings Call Transcript - Insider Monkey
Beyond the Balance Sheet: What SWOT Reveals About Bausch & Lomb Corp (BLCO) - GuruFocus
Bausch + Lomb Signals Profitable Growth After Record Year - TipRanks
Bausch + Lomb Lifts 2025 Revenue on Dry Eye and Vision Care Growth - TipRanks
Bausch + Lomb Corporation Q4 2025 Earnings Call Summary - Yahoo Finance
Bausch & Lomb Earnings: Nice Results from Growth Momentum, Solid Execution, and Pipeline Investment - Morningstar Canada
Bausch & Lomb Looks for Long-Term Growth Fueled by Innovation and Pipeline Investments - Morningstar
1st contact lens innovation since 1999 is coming: Bausch + Lomb CEO - Yahoo Finance
Bausch + Lomb Q4 Earnings Call Highlights - Yahoo Finance
Bausch + Lomb (BLCO) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates - Yahoo Finance
Bausch + Lomb (BLCO) Lags Q4 Earnings Estimates - Yahoo Finance
Bausch + Lomb’s (NYSE:BLCO) Q4 CY2025: Beats On Revenue - Yahoo Finance
Bausch + Lomb shares edge higher despite earnings miss as revenue tops estimates - Investing.com
Bausch + Lomb Q4 and Full-Year 2025 Financial Results - TradingView
Bausch + Lomb Announces Fourth-Quarter and Full-Year 2025 Results, Provides 2026 Guidance - The AI Journal
Bausch + Lomb stock hits 52-week high at $17.87 By Investing.com - Investing.com India
Bausch + Lomb stock hits 52-week high at $17.87 - Investing.com
Stifel raises Bausch & Lomb stock price target on Miebo strength - Investing.com Canada
Bausch + Lomb earnings on deck as Miebo profitability looms - Investing.com Nigeria
Bausch + Lomb earnings on deck as Miebo profitability looms By Investing.com - Investing.com UK
Bausch + Lomb (BLCO) Q4 Earnings: What To Expect - Yahoo Finance
Ahead of Bausch + Lomb (BLCO) Q4 Earnings: Get Ready With Wall Street Estimates for Key Metrics - Yahoo Finance
Should Bausch + Lomb’s Mandatory AI Training Strategy Reshape the BLCO Execution Story? - Yahoo Finance
Assessing Bausch + Lomb (BLCO) Valuation As Shorter Term Shareholder Returns Improve - Yahoo Finance
Aug PreEarnings: Will Bausch Lomb Corporation outperform its industry peersQuarterly Trade Review & Weekly Stock Performance Updates - baoquankhu1.vn
The Truth About Bausch + Lomb Corp: Is This Eye-Care Giant Quietly Winning While No One’s Looking? - AD HOC NEWS
Bausch + Lomb CEO: Standing still is the new falling behind - Fortune
Nicox : Présentation des données des études de Phase 3 de NCX 470 au congrès annuel 2026 de l’American Glaucoma Society (AGS) - GlobeNewswire Inc.
3 Reasons to Sell BLCO and 1 Stock to Buy Instead - Barchart.com
Bausch + Lomb (NYSE:BLCO) Seems To Be Using A Lot Of Debt - 富途牛牛
Bausch + Lomb (NYSE:BLCO) Shares Down 0.9%What's Next? - MarketBeat
Published on: 2026-02-02 10:13:14 - baoquankhu1.vn
Bausch + Lomb Likely to Report a Q4 Beat on FX Tailwinds, Robust Performance of Eye Disease Portfolio, RBC Says - marketscreener.com
RBC Capital Maintains Bausch + Lomb Corp.(BLCO.US) With Buy Rating, Raises Target Price to $21 - 富途牛牛
Bausch & Lomb stock price target raised to $21 from $19 at RBC Capital - Investing.com Nigeria
Bausch & Lomb stock price target raised to $21 from $19 at RBC Capital By Investing.com - Investing.com South Africa
Bausch Health stock unchanged as Phase 3 RED-C trial fails primary endpoint - Investing.com India
Bausch + Lomb Corp: Eyes On The Numbers As BLCO Tests Investor Patience - AD HOC NEWS
BLCO vs. HQY: Which Stock Is the Better Value Option? - Yahoo Finance
Growth Value: Is MLPR attractive for institutional investorsQuarterly Earnings Report & Proven Capital Preservation Tips - baoquankhu1.vn
Bausch + Lomb Will Release Fourth-Quarter and Full-Year 2025 Financial Results on Feb. 18 - BioSpace
Press Release: Bausch + Lomb Will Release Fourth-Quarter and Full-Year 2025 Financial Results on Feb. 18 - 富途资讯
Stifel reiterates Hold rating on Bausch & Lomb stock amid competition concerns By Investing.com - Investing.com Nigeria
Stifel reiterates Hold rating on Bausch & Lomb stock amid competition concerns - Investing.com Nigeria
Bausch + Lomb Corporation (NYSE:BLCO) Receives Consensus Recommendation of "Hold" from Analysts - MarketBeat
Bausch Lomb Corp (BLCO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.74%
0.34%
자본화:
|
볼륨(24시간):